20 Leading Antibiotics Producers Discussed in New Visiongain Report Recently Published at MarketPublishers.com

Share Article

New research report “Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022” elaborated by Visiongain has been recently published by Market Publishers Ltd. The report finds that treatments targeting clostridium difficile and MRSA infections are expected to make a difference to 2022.

TD The Market Publishers Ltd

http://marketpublishers.com/

Currently, there are many opportunities in the antibiotics industry and market, especially with the development of new classes of antibacterial drug. In particular, treatments targeting clostridium difficile and MRSA infections are expected to make a difference to 2022.

Patent expiries are predicted to challenge antibiotic manufacturers throughout this decade, with generic pharmaceutical sales prominent and growing. Companies are likely to use product lifecycle management to reduce declines of brands and stimulate their sales.

New research report “Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022” elaborated by Visiongain has been recently published by Market Publishers Ltd.

Report Details:

Title: Pharma Leader Series: Top 20 Antibacterial Drug Manufacturers 2012-2022
Published: June, 2012
Pages: 185
Price: US$ 2,642.00
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/drugs_biotechnology/pharma_leader_series_top_20_antibacterial_drug_manufacturers_2012_2022.html

The research report offers an up-close look at the 20 leading companies within the antibacterial drugs market. In particular, the study features:

  •     assessment of top 20 antibacterial drug manufacturers’ activities and outlooks from 2012;
  •     analysis of overall world market and submarket revenue forecasts to 2022;
  •     analysis of leading companies, with revenue forecasts to 2022;
  •     comparative analysis of trends among antibacterial manufacturers;
  •     analysis of existing revenues and operational data for leading companies;
  •     review of pipeline developments, with assessments of R&D trends and potential;
  •     analysis of recent licensing deals and acquisitions;
  •     insight into competition and opportunities influencing sales;
  •     prospects for emerging companies and antimicrobial specialists;
  •     industry and market drivers and restraints from 2012.

Report Contents:

1. Executive Summary

1.1 Leading Antibacterial Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.4.1 Drugs Considered for this Report
    1.4.1.1 Ophthalmic and Dermatologic Antibacterials
1.4.2 The Chinese Antibacterial Drugs Market
1.5 Terminology Used in this Report

2. An Introduction to the Antibacterial Drugs Market

2.1 Bacterial Infections and Antibacterial Drugs
2.1.1 Gram-Positive and Gram-Negative Infections
2.1.2 Treating Bacterial Infections
2.2 The Antibacterial Drugs Market 2011
2.2.1 Leading Classes of Antibacterial Drug
    2.2.1.1 Cephalosporins
    2.2.1.2 Penicillins
    2.2.1.3 Fluoroquinolones
    2.2.1.4 Macrolides
    2.2.1.5 Carbapenems
2.3 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
2.3.1 Market Drivers 2012-2022
2.3.2 Market Restraints 2012-2022
2.4 Leading Antibacterial Drug Manufacturers in 2011
2.4.1 Company Comparison
    2.4.1.1 Broad Product Portfolios
    2.4.1.2 Regional Focus
    2.4.1.3 Future of the Antibacterial Drugs Industry

3. The Leading US Big Pharma Antibacterial Drug Manufacturers 2012-2022

3.1 Pfizer
3.1.1 A Long History in Antibacterials
3.1.2 Antibacterial Product Portfolio
    3.1.2.1 Dalacin (Clindamycin)
    3.1.2.2 Sulperazon (Cefoperazone/Sulbactam)
    3.1.2.3 Tygacil (Tigecycline)
    3.1.2.4 Unasyn (Ampicillin/Sulbactam)
    3.1.2.5 Zithromax (Azithromycin)
    3.1.2.6 Zosyn (Piperacillin/Tazobactam)
    3.1.2.7 Zyvox (Linezolid)
3.1.3 Antibacterial Revenue 2011
3.1.4 Pipeline
    3.1.4.1 Pipeline 2007-2010
    3.1.4.2 PNU-100480 (Sutezolid)
3.1.5 Pfizer Antibacterials: SWOT Analysis
3.1.6 Antibacterial Revenue Forecast 2012-2022
3.2 Merck & Co.
3.2.1 Antibacterial Product Portfolio
    3.2.1.1 Avelox (Moxifloxacin)
    3.2.1.2 Invanz (Ertapenem)
    3.2.1.3 Primaxin (Imipenem/Cilastatin)
3.2.2 Antibacterial Revenue 2011
3.2.3 Recent Licensing Deals
3.2.4 Pipeline
    3.2.4.1 MK-3415A
    3.2.4.2 MK-7655
3.2.5 Merck Antibacterials: SWOT Analysis
3.2.6 Antibacterial Revenue Forecast 2012-2022
3.3 J&J
3.3.1 Antibacterial Product Portfolio
    3.3.1.1 Doribax (Doripenem)
    3.3.1.2 Levaquin (Levofloxacin)
3.3.2 Antibacterial Revenue 2011
    3.3.2.1 Patent Challenges
3.3.3 Decreasing Investment in Antibacterials
3.3.4 Pipeline: TMC207
3.3.5 J&J Antibacterials: SWOT Analysis
3.3.6 Antibacterial Revenue Forecast 2012-2022
3.4 Abbott Laboratories
3.4.1 Antibacterial Product Portfolio
    3.4.1.1 Biaxin (Clarithromycin)
3.4.2 Antibacterial Revenue 2011
3.4.3 Abbott Antibacterials: SWOT Analysis
3.4.4 Antibacterial Revenue Forecast 2012-2022

4. The Leading European Big Pharma Antibacterial Drug Manufacturers 2012-2022

4.1 GSK
4.1.1 Antibacterial Product Portfolio
    4.1.1.1 Augmentin (Amoxicillin/Clavulanate)
    4.1.1.2 Bactroban (Mupirocin)
    4.1.1.3 Duac (Clindamycin/Benzoyl Peroxide)
    4.1.1.4 Fortum (Ceftazidime)
    4.1.1.5 Zinnat (Cefuroxime)
4.1.2 Antibacterial Revenue 2011
4.1.3 Antibacterials in the US
4.1.4 Pipeline
    4.1.4.1 GSK2251052
    4.1.4.2 GSK1322322
4.1.5 GSK Antibacterials: SWOT Analysis
4.1.6 Antibacterial Revenue Forecast 2012-2022
4.2 Novartis
4.2.1 Antibacterial Product Portfolio
    4.2.1.1 Ciprodex (Ciprofloxacin/Dexamethasone)
    4.2.1.2 Cubicin (Daptomycin)
    4.2.1.3 Moxeza (Moxifloxacin)
    4.2.1.4 TOBI Podhaler (Tobramycin Inhalation Powder)
    4.2.1.5 Vigamox (Moxifloxacin)
4.2.2 Antibacterial Revenue 2011
4.2.3 Entering and Exiting Licensing Agreements
4.2.4 Pipeline
    4.2.4.1 Finafloxacin
    4.2.4.2 LFF571
4.2.5 Novartis Antibacterials: SWOT Analysis
4.2.6 Antibacterial Revenue Forecast 2012-2022
4.3 Bayer
4.3.1 Antibacterial Product Portfolio
    4.3.1.1 Avelox (Moxifloxacin)
    4.3.1.2 Cipro (Ciprofloxacin)
4.3.2 Antibacterial Revenue 2011
4.3.3 Avelox Patent Challenges
4.3.4 Bayer and Trius Therapeutics
4.3.5 Pipeline
    4.3.5.1 Ciprofloxacin Inhale
    4.3.5.2 Amikacin Inhale
4.3.6 Bayer Antibacterials: SWOT Analysis
4.3.7 Antibacterial Revenue Forecast 2012-2022
4.4 AstraZeneca
4.4.1 Antibacterial Product Portfolio
    4.4.1.1 Cubicin (Daptomycin)
    4.4.1.2 Merrem (Meropenem)
    4.4.1.3 Zinforo (Ceftaroline)
4.4.2 Antibacterial Revenue 2011
4.4.3 AstraZeneca Acquires Novexel
4.4.4 Pipeline
    4.4.4.1 CAZ-AVI
    4.4.4.2 CEF104
    4.4.4.3 NXL103
    4.4.4.4 AZD5847
4.4.5 AstraZeneca Antibacterials: SWOT Analysis
4.4.6 Antibacterial Revenue Forecast 2012-2022
4.5 Roche
4.5.1 Antibacterial Product Portfolio
...

More new market research reports by the publisher can be found at Visiongain page.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website